Rudolph Navari

7PUBLICATIONS
11CO-AUTHORS
Autonomic nervous systemCancer therapy (excl. chemotherapy and radiation therapy)Pharmacology and pharmaceutical sciences not elsewhere classifiedChemotherapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Aug 09, 2025
Individual patient data meta-analysis of NEPA versus aprepitant-based antiemetic regimens for preventing chemotherapy-induced nausea and vomiting.

Rudolph M Navari, Timothy Tyler, Naoki Inui

|Mar 27, 2025
NEPA (Netupitant/Palonosetron) for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Patients Receiving Highly or Moderately Emetogenic Chemotherapy Who Experienced Breakthrough CINV in Cycle 1 of Chemotherapy: A Phase II Clinical Trial.

Rudolph M Navari, Erminio Bonizzoni

|Mar 19, 2025
Nausea and vomiting in an evolving anticancer treatment landscape: long-delayed and emetogenic antibody-drug conjugates.

Yeon Hee Park, Giampaolo Bianchini, Javier Cortés

|Aug 04, 2023
Single-dose NEPA versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy.

Laurent Zelek, Rudolph Navari, Matti Aapro

|Apr 21, 2021
Single-dose netupitant/palonosetron versus 3-day aprepitant for preventing chemotherapy-induced nausea and vomiting: a pooled analysis.

Rudolph M Navari, Gary Binder, Erminio Bonizzoni

|Apr 01, 2021
Low-dose olanzapine, sedation and chemotherapy-induced nausea and vomiting: a prospective randomized controlled study.

Sandip Mukhopadhyay, Premnath Dutta, Sanatan Banerjee

Pageof 2

Frequent Collaborators

2 joint publications

Eric J Roeland

1 joint publications

Sandip Mukhopadhyay

1 joint publications

Timothy Tyler

1 joint publications

Naoki Inui